Parathyroidectomy and Mobility Study

Egyéb feltételek

• Inclusion:
• Age ≥ 60 years
• Biochemical diagnosis of hypercalcemic (corrected serum calcium >10.2 mg/dL or ionized serum calcium >1.31 mmol/dL or 5.2 mg/dL on at least one serum sample) primary hyperparathyroidism as determined by board-certified endocrinologist or endocrine surgeon
• Undergoing parathyroidectomy at UF Health
• Willing and able to give informed consent; Exclusion:
• Failure to provide informed consent
• Biochemical diagnosis of eucalcemic primary hyperparathyroidism (corrected serum calcium ≤10.2 mg/dL or ionized serum calcium ≤1.31 mmol/dL or 5.2 mg/dL on at least one serum sample)
• Elected not to undergo parathyroidectomy at UF Health
• Major surgery as deemed by principal investigator or hip/knee replacement in the past 6 months
• Fractures to the hands, arms or legs within the last 6 months
• Traumatic accident (i.e. motor vehicle collision, fall from elevation, etc.) resulting in orthopedic trauma or requiring prolonged immobilization (>2 weeks) within the last 6 months
• Blood transfusion within the past 3 months
• Self-reported myocardial infarction, cerebrovascular accident, or unstable angina within the past 6 months
• NYHA Class 3 or 4 congestive heart failure
• Major psychiatric disorder
• Cancer requiring treatment in the past 1 year (including metastatic cancer), except for locally treated non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer)
• Renal failure requiring hemodialysis or peritoneal dialysis
• Use of bone-modifying therapies (alendronate [Fosamax], zoledronic acid [Reclast], denosumab [Prolia or Xgeva], or romosozumab [Evenity]) within 1 month of planned surgery
• Planning to permanently leave the area within 3 months of parathyroidectomy
• Vision or hearing impairment - defined as unable to read or listen/follow instructions despite the use of maximal assistive devices (i.e. contact lenses, glasses, hearing aids, etc.)
• Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment